Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18758839 | STABLE NIMODIPINE PARENTERAL FORMULATION | June 2024 | March 2025 | Allow | 9 | 1 | 1 | No | No |
| 18643086 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | April 2024 | May 2025 | Allow | 13 | 2 | 0 | No | No |
| 18641845 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18641848 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18616858 | Cannabinoid Pouch | March 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18616577 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18616603 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18437368 | CAPSULE FORMULATIONS | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18429916 | METHODS OF PEST CONTROL IN SOYBEAN | February 2024 | June 2025 | Allow | 17 | 1 | 0 | No | No |
| 18426211 | 9-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18426092 | 9-(6-FLOURO-2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18421535 | 2-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 1 | 1 | No | No |
| 18396828 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION | December 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18538502 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18514306 | MODIFIED WOUND DRESSINGS | November 2023 | November 2024 | Allow | 12 | 1 | 0 | No | No |
| 18387755 | 4-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]ISOQUINOLIN-3-OL AS AN ANTIMICROBIAL COMPOUND | November 2023 | April 2024 | Allow | 5 | 1 | 1 | No | No |
| 18387202 | 9-(6-FLOURO-2-HYDROXYOUINOLIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18502663 | ORAL CANNABINOID PRODUCT WITH LIPID COMPONENT | November 2023 | April 2025 | Allow | 17 | 1 | 1 | No | No |
| 18488231 | CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLD | October 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18487995 | 2-[(1,3-BENZOTHIAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | November 2024 | Abandon | 13 | 3 | 1 | No | No |
| 18379966 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18485929 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18378009 | Synthesis and Antimicrobial Uses of Dinuclear Silver(I) Pyrazolates | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18474782 | Perfume Compositions | September 2023 | December 2024 | Allow | 14 | 1 | 1 | No | No |
| 18474798 | Perfume Compositions | September 2023 | March 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18368097 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | September 2023 | July 2024 | Allow | 10 | 1 | 0 | No | No |
| 18243299 | NON-SURFACTANT TYPE OIL-WATER DISPERSION COMPOSITION, NON-SURFACTANT TYPE WATER-OIL DISPERSION COMPOSITION, AND MANUFACTURING METHODS FOR BOTH COMPOSITIONS | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18236466 | PERSONAL LUBRICANTS COMPRISING LAMBDA-CARRAGEENAN | August 2023 | May 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18235855 | PRESERVATION OF PERSONAL CARE COMPOSITIONS | August 2023 | January 2025 | Allow | 17 | 1 | 1 | No | No |
| 18341541 | METHOD FOR DEPOT CREATION DURING TRANSDERMAL DRUG DELIVERY | June 2023 | December 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18337974 | METHODS FOR TREATING ALZHEIMER'S DISEASE WITH DONEPEZIL TRANSDERMAL SYSTEM | June 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18206141 | NOVEL NANOEMULSIONS COMPRISING FATTY ACID AND N-ACYL DERIVATIVES OF AMINO ACID SALT | June 2023 | March 2025 | Allow | 21 | 2 | 1 | No | Yes |
| 18329992 | METHODS AND COMPOSITIONS FOR TREATING DIABETIC FOOT ULCERS | June 2023 | January 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18324472 | METHODS OF PEST CONTROL IN SOYBEAN | May 2023 | March 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18319794 | OPHTHALMIC EMULSION | May 2023 | December 2024 | Allow | 19 | 1 | 1 | No | No |
| 18309804 | SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF | April 2023 | March 2024 | Allow | 11 | 2 | 0 | No | No |
| 18303387 | DRUG DELIVERY SYSTEM FOR TREATING DISEASE | April 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18128922 | PHARMACEUTICAL FORMULATIONS | March 2023 | February 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18109349 | Nutritional Supplement | February 2023 | September 2023 | Allow | 7 | 0 | 0 | No | No |
| 18109568 | Formulations for the Delivery of Autophagy Stimulating Trehalose | February 2023 | June 2024 | Allow | 16 | 1 | 1 | No | No |
| 18094080 | ASCORBATE IN THE PREVENTION OF STATIN INDUCED VASCULAR CALCIFICATION | January 2023 | October 2023 | Allow | 10 | 1 | 1 | No | No |
| 18090128 | FRAGRANCE COMPOSITIONS CONTAINING NORBORNENE DERIVATIVES FOR PERSONAL CARE PRODUCTS | December 2022 | September 2023 | Allow | 9 | 0 | 0 | No | No |
| 18085720 | PERSONAL LUBRICANTS COMPRISING LAMBDA-CARRAGEENAN | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18011796 | CONDOMS LUBRICATED WITH ANTIVIRAL LUBRICIOUS COMPOSITIONS CONTAINING LAMBDA-CARRAGEENAN | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18062351 | Activated Cannabinoid Controlled Release Compound Tablet and Method of Forming The Same | December 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 18057554 | Topical Therapy of Skin Fibrosis and Melanoma | November 2022 | May 2025 | Abandon | 30 | 4 | 1 | No | No |
| 17988412 | Cannabinoid Pouch | November 2022 | December 2023 | Allow | 13 | 1 | 0 | No | No |
| 17985636 | COMBINATIONS OF NANOPARTICLE-ENCAPSULATED CARGO ENTITIES AND METHODS FOR MAKING AND USING SAME | November 2022 | September 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17985748 | METHOD AND KIT FOR PROVIDING A CUSTOMIZABLE NAIL-BITING AND FINGER SUCKING PREVENTION TREATMENT | November 2022 | May 2025 | Allow | 30 | 4 | 0 | No | No |
| 18054055 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | November 2022 | June 2024 | Abandon | 19 | 2 | 0 | No | No |
| 17982950 | WATER-SOLUBLE MICROENCAPSULATED CANNABINOID EXTRACT POWDER AND METHOD OF MAKING THE SAME | November 2022 | February 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17970639 | Aqueous Solution For Use In Cleaning Via Irradiation By Ultraviolet Rays And/Or Near-Ultraviolet Visible Light And/Or Light In 800-900 NM Near-Infrared Region, Dentifrice Including Said Solution, Dental Treatment Device, Toothbrush, And Tooth Cleaning Met | October 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17970632 | Aqueous Solution For Use In Cleaning Via Irradiation By Ultraviolet Rays And/Or Near-Ultraviolet Visible Light And/Or Light In 800-900 NM Near-Infrared Region, Dentifrice Including Said Solution, Dental Treatment Device, Toothbrush, And Tooth Cleaning Met | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17967834 | PROCESSES FOR PRODUCING PARTICLES OF AT LEAST ONE POLYHYDROXYALKANOATE (PHA) | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17963607 | INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF | October 2022 | March 2025 | Abandon | 29 | 2 | 0 | No | Yes |
| 17958876 | VOLATILE OILY COMPOSITION | October 2022 | August 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17935667 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION | September 2022 | September 2023 | Allow | 12 | 1 | 0 | No | No |
| 17934727 | Abiotic Anti-VEGF Nanoparticle | September 2022 | November 2023 | Allow | 14 | 1 | 0 | No | No |
| 17934056 | TRANSDERMAL CARRIER | September 2022 | December 2023 | Allow | 15 | 1 | 0 | No | No |
| 17945221 | HERBICIDAL COMPOUNDS | September 2022 | April 2024 | Allow | 19 | 2 | 1 | No | No |
| 17929396 | FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | September 2022 | March 2024 | Allow | 19 | 2 | 0 | No | No |
| 17878947 | ACTIVE AGENT-CONTAINING ARTICLES | August 2022 | May 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17874818 | LIPID COMPOSITION FOR THE DELIVERY OF THERAPEUTIC CARGOS | July 2022 | December 2024 | Abandon | 28 | 3 | 1 | No | No |
| 17863884 | DRUG DELIVERY SYSTEM | July 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17863428 | SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF | July 2022 | February 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17861413 | Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and Use | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17861210 | CLEANSING PAD AND COMPOSITION FOR REDUCING TOXINS | July 2022 | May 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17758554 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | July 2022 | July 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17850565 | METHOD FOR PREPARATION OF TISSUE ADHESIVE PATCHES | June 2022 | July 2023 | Allow | 13 | 0 | 1 | No | No |
| 17850018 | SOLID DOSAGE FORM OF N-1-PYRROLIDINE-N-5-(3-TRIFLUOROMETHOXY)PHENYL BIGUANIDE AND USES THEREOF | June 2022 | July 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17835684 | NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY | June 2022 | September 2024 | Allow | 28 | 1 | 1 | No | No |
| 17745937 | HIGH LOAD DISPERSIONS | May 2022 | June 2023 | Allow | 13 | 1 | 0 | No | No |
| 17744192 | POLYMERIC TREATMENT COMPOSITIONS | May 2022 | January 2024 | Allow | 20 | 1 | 1 | No | No |
| 17726865 | CROSS-LINKED PROTEIN FOAMS AND METHODS OF USING THEREOF A POLYVALENT CELLULAR SCAFFOLD | April 2022 | July 2023 | Allow | 15 | 1 | 0 | No | No |
| 17724650 | BIOPOLYMER COMPOSITIONS, SCAFFOLDS AND DEVICES | April 2022 | February 2025 | Allow | 34 | 4 | 1 | No | No |
| 17769834 | Fungicide Mixtures | April 2022 | April 2025 | Allow | 36 | 1 | 1 | No | No |
| 17767142 | HAIR TREATMENT COMPOSITIONS | April 2022 | July 2025 | Allow | 39 | 1 | 1 | No | No |
| 17713608 | Composition Comprising Cannabis Extracts and Method of Manufacturing Same | April 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17710972 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | March 2022 | September 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17705752 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS | March 2022 | November 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17656642 | BIOMEDICAL COMPOSITE MATERIAL AND PREPARATION METHOD THEREFOR | March 2022 | August 2023 | Allow | 17 | 1 | 1 | Yes | No |
| 17656643 | AN ABSORBABLE BIOMEDICAL POLYLACTIC ACID COMPOSITE MATERIAL AND PREPARATION METHOD THEREFOR | March 2022 | August 2023 | Allow | 17 | 1 | 1 | Yes | No |
| 17703778 | CANNABINOID FORMULATION AND METHOD OF MAKING THEREOF | March 2022 | September 2024 | Abandon | 30 | 1 | 1 | Yes | No |
| 17687522 | METHODS FOR IMPROVING RESPIRATORY SYSTEM HEALTH AND INCREASING THE CONCENTRATION OF HYPOTHIOCYANATE ION IN VERTEBRATE LUNGS | March 2022 | January 2024 | Allow | 22 | 2 | 1 | No | No |
| 17677648 | METHODS AND COMPOSITIONS FOR MAKING AND USING COMPATIBLE INSECTICIDAL PROTEINS | February 2022 | May 2025 | Allow | 38 | 1 | 0 | No | No |
| 17672589 | PERSONAL CARE SPRAY COMPOSITIONS AND METHODS COMPRISING TRANS-1-CHLORO-3,3,3-TRIFLUOROPROPENE | February 2022 | March 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17629160 | NEAR-INFRARED-SHIELDING MATERIAL | January 2022 | June 2025 | Allow | 41 | 1 | 1 | No | No |
| 17579579 | CANNABINOID POUCHES | January 2022 | October 2022 | Allow | 8 | 2 | 0 | Yes | No |
| 17569913 | ELASTOMER COATED POWDERS | January 2022 | April 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17568790 | VARIABLE-SIZE HYDROPHOBICALLY-MODIFIED POLYMERS | January 2022 | October 2023 | Abandon | 22 | 1 | 1 | No | No |
| 17622861 | USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS | December 2021 | January 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17551982 | SHAVING AID COMPRISING A BENEFIT AGENT | December 2021 | August 2024 | Allow | 33 | 4 | 1 | No | No |
| 17551512 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | December 2021 | January 2023 | Abandon | 13 | 2 | 0 | Yes | No |
| 17545878 | CAPSULE FORMULATIONS | December 2021 | February 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17530347 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17523334 | STABLE NIMODIPINE PARENTERAL FORMULATION | November 2021 | April 2024 | Allow | 29 | 2 | 1 | No | No |
| 17516564 | ANTIBACTERIAL AND/OR ANTIVIRAL TREATMENT COMPOSITION FOR OPTICAL COMPONENTS AND METHOD OF APPLICATION | November 2021 | April 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17513990 | Synthesis and Antimicrobial Uses of Dinuclear Silver(I) Pyrazolates | October 2021 | July 2023 | Allow | 20 | 1 | 1 | No | No |
| 17605074 | HAIR CONDITIONING COMPOSITION | October 2021 | June 2025 | Allow | 44 | 1 | 1 | No | No |
| 17504706 | FILLED UNCURED RUBBER COMPOUND FOR LESS LETHAL AMMUNITION AND DRUG-ELUTING ELECTROSPUN FIBER MAT | October 2021 | August 2024 | Allow | 34 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SONG, JIANFENG.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SONG, JIANFENG works in Art Unit 1613 and has examined 833 patent applications in our dataset. With an allowance rate of 54.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.
Examiner SONG, JIANFENG's allowance rate of 54.6% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SONG, JIANFENG receive 2.15 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SONG, JIANFENG is 26 months. This places the examiner in the 59% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +35.8% benefit to allowance rate for applications examined by SONG, JIANFENG. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.4% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.7% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 72.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 57% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 73.8% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 50.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 65.2% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.